ATNM · Actinium Pharmaceuticals, Inc.
$0.86
-0.03 (-2.94%)
At close · Jul 24
Market Cap
$26.98M
Shares
31.37M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Sandesh Seth | CEO | $1,173,200 |
| Steve O’Loughlin | CFO | $581,800 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Sandesh Seth | CEO | $4,704,999 |
| Steve O’Loughlin | CFO | $1,490,000 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Sandesh Seth | CEO | $4,020,167 |
| Steve O’Loughlin | CFO | $1,476,144 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Sandesh Seth | CEO | $2,335,323 |
| Steve O’Loughlin | CFO | $967,034 |
| Mark S. Berger | Chief Medical Officer | $584,357 |
| Dale L. Ludwig | Former Chief Scientific and Technology Officer | $213,068 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Sandesh Seth | CEO | $1,831,728 |
| Mark S. Berger | Chief Medical Officer | $829,958 |
| Steve O’Loughlin | CFO | $818,640 |
| Dale L. Ludwig | Former Chief Scientific and Technology Officer | $817,453 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Sandesh Seth | CEO | $1,102,717 |
| Mark S. Berger | Chief Medical Officer | $554,364 |
| Dale L. Ludwig | Former Chief Scientific and Technology Officer | $496,614 |
| Steve O’Loughlin | CFO | $442,914 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Sandesh Seth | CEO | $1,374,253 |
| Mark S. Berger | Chief Medical Officer | $612,313 |
| Steve O’Loughlin | CFO | $505,552 |
| Dale L. Ludwig | Former Chief Scientific and Technology Officer | $424,695 |